刘进  博士  副教授  硕士研究生导师

  邮箱：jin_liu@hainanu.edu.cn；liujin9108@163.com

  1.教育背景

  2019.09—2022.06，南方医科大学， 药物化学，医学博士；

  2014.09—2017.06，沈阳药科大学， 药物化学，理学硕士；

  2009.09—2013.06，吉林医药学院，     药学，理学学士；

  2.科研情况

  致力于创新小分子药物的研究，在药物设计、合成以及生物评价方面积累了丰富的经验。近年来围绕抗代谢性疾病药物、肿瘤免疫小分子药物和靶向蛋白降解的抗炎药物等研究领域开展了一系列基础与应用研究。近三年科研成果突出，已在J. Med. Chem, Eur J Med Chem等期刊发表SCI论文10篇，申请专利6项，主持科研项目3项。

  3.研究领域

  抗肿瘤药物；

抗代谢性疾病药物；

靶向蛋白降解抗炎药物

4.代表性项目

（1）海南省自然科学基金面上项目，调控固有免疫的STING蛋白降解剂设计、合成及其急性肾损伤治疗研究，8万，主持

（2）太阳集团tyc59972023年本科生课外科研课题，STING蛋白降解剂设计、合成及其急性肾损伤治疗研究，主持

（3）海南省2023年研究生创新科研项目，基于PROTAC的口服STING降解剂的设计、合成及急性肾损伤治疗研究，主持

（4）中组部青年海外高层次人才项目：新型小分子抗癌药物的研究。2017-2022，300万，参与。

（5）广东省科技厅国际合作项目：靶向维生素D受体(VDR)的激动剂作为抗癌药物的研究与开发。2019-2021，50万，参与并结题。

（6）国家自然科学基金面上项目：靶向PD-L1&CXCL12双功能小分子的设计、合成及作为癌症双免疫疗法的研究。2022-2025，55万，参与。

5.代表性成果

2023年SCI论文

(1) Jin Liu*^,#, Yao Cheng^#, Lin Yuan^#, Ting Liu^#, Yong Ruan, Yichang Ren, Ling Li, Sheng Jiang*, Yibei Xiao*, Jianjun Chen*; Discovery and Crystallography Study of Novel Biphenyl Ether and Oxadiazole Thioether (Non-Arylmethylamine)-Based Small-Molecule PD-1/PD-L1 Inhibitors as Immunotherapeutic Agents. J. Med. Chem. 2023 Sep 28;66(18):13172-13188. (中科院一区TOP, IF:7.3)

(2) Yichang Ren^#, Yuxi Wang^#, Jin Liu^#, Ting Liu, Lin Yuan, Chengyong Wu, Zichao Yang, Jianjun Chen; X-ray Crystal Structure-Guided Discovery of Novel Indole Analogues as Colchicine-Binding Site Tubulin Inhibitors with Immune-Potentiating and Antitumor Effects against Melanoma. J. Med. Chem. 2023 May 25;66(10):6697-6714. (中科院一区TOP, IF:7.3)

(3) Fei Tong^#, Jin Liu^#, Yali Zhong, Yingli Xue, Lei Luo, Zhongchao Wang, Lingyan Qiao, Xiuzhi Zhou, Weixin Wang, Jiahui Sun, Miaofang Hong, Jianming Wu, Qibing Mei, Guosheng Wu; Carbon monoxide-propelled nanomotors as an active treatment for renal injury. Applied Materials Today, 32 (2023) 101823. (中科院二区, IF:8.3)

(4) Fei Tong^#, Jin Liu^#, Lei Luo, Lingyan Qiao, Jianming Wu, Guosheng Wu, Qibing Mei; pH/ROS-responsive propelled nanomotors for the active treatment of renal injury. Nanoscale. 2023 Apr 6;15(14):6745-6758. (中科院二区TOP, IF:8.3)

2022年SCI论文

(1) Jin Liu, Yong Ruan, Bulian Deng, Lin Yuan, Yichang Ren, Ling Li, Zicao Yang, Ting Liu, Huiting Zhao, Ruiyao Mai, Jianjun Chen*; Novel CRBN-Recruiting Proteolysis-Targeting Chimeras as Degraders of Stimulator of Interferon Genes with In Vivo Anti-Inflammatory Efficacy. J. Med. Chem. 2022 May 12;65(9):6593-6611 (中科院一区TOP, IF:7.3)

(2) Zean Zhao^#, Jin Liu^#, Lin Yuan, Zichao Yang, Peihua Kuang, Hui Liao, Jian Luo, Huancun Feng, Fengxin Zheng, Yongjun Chen, Ting Wu, Jiayin Guo, Ying Cao, Yang Yang, Cuiting Lin, Qun Zhang*, Jianjun Chen*, Jianxin Pang*; Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents. Eur J Med Chem. 2022 Agu 18; 242:114682. (中科院一区TOP, IF:6.7)

(3) Zean Zhao^#, Jin Liu^#, Peihua Kuang, Jian Luo, Goverdhan Surineni, Xiaolin Cen, Ting Wu, Ying Cao, Pingzheng Zhou, Jianxin Pang, Qun Zhang, Jianjun Chen^*; Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemia. Eur J Med Chem. 2022 Feb 5; 229:114092. (中科院一区TOP, IF:6.7)

(4) Ling Li^#, Jin Liu^#, Huiting Zhao, Bulian Deng, Zichao Yang, Yichang Ren,Ruiyao Mai, Junli Huang, Jianjun Chen*; Discovery of Thieno [2,3-d] pyrimidine-based KRAS G12D inhibitors as potential anticancer agents via combinatorial virtual screening. Eur J Med Chem. 2022 March 3; 233: 114243 (中科院一区TOP, IF:6.7)

(5) Yuanxing Zhi^#, Jin Liu^#, Peihua Kuang, Xin Zhang, Ziwei Xu, Pingzheng Zhou*, Jianjun Chen*. Novel DCPIB analogs as dual inhibitors of VRAC/TREK1 channels reduced cGAS-STING mediated interferon responses. Biochem Pharmacol. 2022 March 10; 199: 114988 (中科院二区TOP, IF:5.8)

2019年之前SCI论文

(1) Jin Liu, Daiying Zuo, Tongfei Jing, Ming Guo, Lingyun Xing, Wenyu Zhang, Jianwen Zhao, Jiwei Shen, Ping Gong, Dajun Zhang, Xin Zhai*. Optimization and biological evaluation of novel 5,7-diarylimidazo [1,2-a] pyridine-8-carbonitriles as potent antitubulin agents. Bioorg. Med. Chem. 2017,25(15):4088-4099 (IF:3.461)

著作专利

(1)刘进，吴迪等，DPP-Ⅳ抑制剂特力利汀的合成工艺改进[J]. 中国药物化学杂志

(2) 陈建军，刘进。一种富马酸酰胺类化合物或其药学上可接受的盐及其制备方法和应用。CN114085215B

(3) 庞建新，陈建军，赵泽安，刘进，吴婷，田元新。杂环芳酰胺类化合物及其制备方法和应用CN115160314B

(4) 陈建军，彭孝鹏，李玲，任益昌，刘进。一种N-羰基-9,10-二氢吖啶类化合物及其应用。CN111018780A

(5) 庞建新，陈建军，田元新，吴婷，赵泽安，邝沛华，刘进，李璐，李咏梅。一种吡啶3-胺衍生物及其制备方法和应用。CN113979931A

欢迎具有药学、化学、生物学背景的同学报考本课题组研究生。